JP2012514997A5 - - Google Patents

Download PDF

Info

Publication number
JP2012514997A5
JP2012514997A5 JP2011545812A JP2011545812A JP2012514997A5 JP 2012514997 A5 JP2012514997 A5 JP 2012514997A5 JP 2011545812 A JP2011545812 A JP 2011545812A JP 2011545812 A JP2011545812 A JP 2011545812A JP 2012514997 A5 JP2012514997 A5 JP 2012514997A5
Authority
JP
Japan
Prior art keywords
monovalent antibody
recombinant monovalent
region
recombinant
antibody according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011545812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012514997A (ja
JP5755148B2 (ja
Filing date
Publication date
Priority claimed from EP09290029A external-priority patent/EP2210902A1/en
Application filed filed Critical
Publication of JP2012514997A publication Critical patent/JP2012514997A/ja
Publication of JP2012514997A5 publication Critical patent/JP2012514997A5/ja
Application granted granted Critical
Publication of JP5755148B2 publication Critical patent/JP5755148B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011545812A 2009-01-14 2010-01-13 組換え一価抗体 Active JP5755148B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09290029.9 2009-01-14
EP09290029A EP2210902A1 (en) 2009-01-14 2009-01-14 Recombinant monovalent antibodies
PCT/IB2010/000196 WO2010082136A1 (en) 2009-01-14 2010-01-13 Recombinant monovalent antibodies

Publications (3)

Publication Number Publication Date
JP2012514997A JP2012514997A (ja) 2012-07-05
JP2012514997A5 true JP2012514997A5 (enExample) 2013-02-28
JP5755148B2 JP5755148B2 (ja) 2015-07-29

Family

ID=40435756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011545812A Active JP5755148B2 (ja) 2009-01-14 2010-01-13 組換え一価抗体

Country Status (5)

Country Link
US (2) US9587023B2 (enExample)
EP (2) EP2210902A1 (enExample)
JP (1) JP5755148B2 (enExample)
CA (2) CA2749627C (enExample)
WO (1) WO2010082136A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210902A1 (en) * 2009-01-14 2010-07-28 TcL Pharma Recombinant monovalent antibodies
US8785604B2 (en) * 2010-02-18 2014-07-22 Effimune Anti-CD28 humanized antibodies
EP2905290B1 (en) 2012-10-05 2019-12-04 Kyowa Kirin Co., Ltd. Heterodimeric protein composition
MX383614B (es) 2015-05-21 2025-03-14 Harpoon Therapeutics Inc Proteinas de union triespecificas y metodos de uso.
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
AU2017267793B2 (en) 2016-05-20 2024-01-25 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
ES2975750T3 (es) * 2016-08-26 2024-07-12 Sanofi Sa Anticuerpos multiespecíficos que facilitan el emparejamiento selectivo de las cadenas ligeras
KR102275008B1 (ko) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
US10844134B2 (en) 2016-11-23 2020-11-24 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
WO2018160754A2 (en) * 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
SI3694529T1 (sl) 2017-10-13 2024-10-30 Harpoon Therapeutics, Inc. Trispecifične beljakovine in načini uporabe
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
BR112020023330A2 (pt) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
KR20220008866A (ko) 2019-05-14 2022-01-21 하푼 테라퓨틱스, 인크. EpCAM 결합 단백질 및 사용 방법
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
CA3252619A1 (en) 2022-02-23 2023-08-31 Xencor, Inc. Anti-CD28 and anti-PSMA antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
ES2353273T3 (es) 2000-12-26 2011-02-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos anti-cd28.
US7053202B2 (en) * 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
AU2004309347B2 (en) * 2003-12-19 2010-03-04 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US20060094062A1 (en) * 2004-11-01 2006-05-04 Medimmune, Inc. Ultra high throughput capture lift screening methods
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
CN103232540A (zh) * 2006-02-01 2013-08-07 赛法隆澳大利亚控股有限公司 结构域抗体构建体
US20100255012A1 (en) * 2007-05-31 2010-10-07 Genmab A/S Recombinant fucose modified monovalent half-antibodies obtained by molecular engineering
US20110097339A1 (en) * 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
EP2210902A1 (en) * 2009-01-14 2010-07-28 TcL Pharma Recombinant monovalent antibodies
US8785604B2 (en) * 2010-02-18 2014-07-22 Effimune Anti-CD28 humanized antibodies

Similar Documents

Publication Publication Date Title
JP5755148B2 (ja) 組換え一価抗体
JP2020508655A5 (enExample)
RU2011116927A (ru) Антитела против интерлейкина 17 (ил-17) человека и их применение
JP2012501669A5 (enExample)
JP2022512684A5 (enExample)
IL275270A (en) Recombinant scavenger cell surface proteins
JP2015519055A5 (enExample)
RU2019100481A (ru) Биспецифические антитела-ингибиторы контрольных точек
JP2019031529A5 (enExample)
JP2017504578A5 (enExample)
RU2013140350A (ru) Антитела против человеческого il33r и их применение
HK1207575A1 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
FI3998285T3 (fi) Cd38:aan ja pd-l1:een sitoutuvia molekyylejä
JP2012501670A5 (enExample)
RU2012142231A (ru) Антитела против csf-1r человека и их применение
JP2019525738A5 (enExample)
JP2013529084A5 (enExample)
JP2013545455A5 (enExample)
FI3561057T3 (fi) Anti-cd3-vasta-aine ja vasta-ainetta sisältäviä molekyylejä
JP2014518883A5 (enExample)
RU2014114172A (ru) Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом
JP2012525829A5 (enExample)
NZ701825A (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
JP2010536396A5 (enExample)
CA3139508A1 (en) Materials and methods for modulating t cell mediated immunity